Retina Vitreous Associates of Florida | St. Petersburg

Research site

(Unclaimed)

Location

4344 Central Avenue, St. Petersburg, Florida, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

JNJ-81201887

RO7200220

BI 764524

Zimura

GT005

Elamipretide

AG-73305

BI 771716

ANX007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 14 total trials

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling

Macular Degeneration

Geographic Atrophy

Other: Sham Procedure

Drug: JNJ-81201887

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling

Neovascular Age-related Macular Degeneration

Drug: LUCENTIS (Ranibizumab Injection)

Device: PDS Implant With Ranibizumab 100 mg/ml

Status recently updated

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...

Enrolling

Active, not recruiting

Geographic Atrophy

Drug: Vonaprument

Other: Sham Administration

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 w...

Enrolling

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Ranibizumab refill exchange

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling

Geographic Atrophy

Biological: OpRegen

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling

Diabetic Retinopathy

Drug: BI 764524

Drug: Aflibercept (Eylea®) - US only

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy (VERDANT)

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Active, not recruiting

Macular Degeneration, Age-related

Geographic Atrophy

Drug: Pegcetacoplan

Drug: Sham comparator to BI 771716

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Active, not recruiting

Age Related Macular Degeneration (ARMD)

Drug: Elamipretide

Drug: Placebo